Navigation Links
Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
Date:10/25/2007

"We look forward to future research efforts to further elucidate the role of AGEs in gastrointestinal complications including diabetic intestinal dysfunction, diabetic enteropathy and diabetic gastroparesis and the role that alagebrium may play in those disease."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties in
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ... the District of New Jersey ... against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... that U.S. Patent No. 6,765,117 is both valid and ... its generic product until the expiration of that patent ...
(Date:8/29/2014)... Aug. 29, 2014 Diseases largely eradicated in ... ago are returning. Measles was declared eliminated in 2000, ... as of August 15—the highest incidence in 20 years. ... department declared whooping cough a problem of "epidemic ... sick and dying from these preventable diseases—in part because ...
(Date:8/29/2014)... 2014 Research and Markets has ... Drugs Market 2014-2018" report to their offering. ... condition that results in demyelination, axonal transection, and neurodegeneration. ... response by the immune system, which targets neurons within ... debilitating disease in which the damage of the myelin ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... China, April 16, 2011 China Medical Equipment ... provider of ultrasound and MRI systems in China, ... portable ultrasound machine. The iuStar100 utilizes Samplify,s high-performance, ... SAM1600 analog to digital converter (ADC) to deliver ...
... Md., April 15, 2011 The U.S. Food and ... or in combination with methotrexate, for the treatment ... children ages 2 years and older. ... Still,s disease, is a rare, potentially life-threatening disorder ...
Cached Medicine Technology:United Imaging Healthcare Leverages Samplify's Analog Front-End Solutions to Deliver New Portable Ultrasound System with Superior Image Quality 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 2FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis 3
(Date:9/2/2014)... At the 50th Annual Mr. Olympia Fitness ... exhibitor at the Las Vegas Convention Center South Hall, ... Booth #374 Sept 19th and 20th 10am-5PM. , ... exercise, diet and supplementation. They pride themselves on creating ... for all Prosupps customers to reach their personal health ...
(Date:9/2/2014)... Health structures explain nearly 20% of the non-adherence ... of a joint ESC-OECD study presented today at ... explained more than 80% of non-adherence. , Professor ... combines clinical data and health structure characteristics of ... the reasons some patients with heart failure do ...
(Date:9/2/2014)... Attorney Robert M. Higgins has been ... Year" for Medical Malpractice Law - Plaintiffs. Higgins ... has been selected for inclusion in The Best Lawyers in ... practice area and designated metropolitan area is honored as the ... received during the peer-review assessments. , The Best ...
(Date:9/2/2014)... AURO the enterprise Canadian Public ... expansion of its leadership team with the appointment of ... Liang joins AURO in conjunction with his current role ... with the operations, product management and engineering teams to ... well as ensuring effective internal and external controls are ...
(Date:9/1/2014)... Securityhunter has experienced rapid growth ... search for a new, larger headquarters. The newly ... the space of our office to 10,000 square feet. ... from glass topped cubicles with doors, to beautiful large conference ... warehouse," says Michael S. Rogers, CEO of Securityhunter. “Our ...
Breaking Medicine News(10 mins):Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Health structures explain nearly 20 percent of non-adherence to heart failure guidelines 2Health News:Robert Higgins Named 2015 Best Lawyers® "Lawyer of the Year" in Boston 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 3Health News:Securityhunter, Inc. Announces the Relocation of Its Corporate Headquarters in Baltimore 2
... in ovarian cancer has provided the most comprehensive and integrated ... Ovarian serous adenocarcinoma tumors from 500 patients were examined by ... reported in the June 30, 2011, issue of Nature ... of ovarian cancer, accounting for about 85 percent of all ...
... (HealthDay News) -- Obesity is a major risk factor ... women, a new study finds. It included more than ... smoked and were followed for 28 years. During that time, ... disease and 487 (27 percent) from cancer. Researchers found ...
... recent study accepted for publication in The Endocrine Society,s ... early, prolonged treatment with the diabetes drug metformin may prevent ... adolescence. PCOS affects 7 to 10 percent of ... of infertility, affecting an estimated 5 to 6 million women ...
... Reporter , TUESDAY, June 28 (HealthDay News) -- A vaccine ... some promise, while another designed to alter insulin production fails, ... results of both studies were slated to be presented Tuesday ... Type 1 diabetes often appears early in life and ...
... are teaming up to offer one of the nation,s ... trucks. Led by the University of Maryland and ... program will target the so-called short-haul "drayage" fleet that ... The effort seeks to double the impact ...
... TUESDAY, June 28 (HealthDay News) -- Mammography screening reduces breast ... according to a new, large-scale Swedish trial. In a ... longest ever -- the researchers found that the benefits of ... In fact, most of the benefits occur more than 10 ...
Cached Medicine News:Health News:The Cancer Genome Atlas completes detailed ovarian cancer analysis 2Health News:The Cancer Genome Atlas completes detailed ovarian cancer analysis 3Health News:Obesity a Major Cause of Early Death in Women: Study 2Health News:Diabetes drug may prevent or delay development of polycystic ovary syndrome 2Health News:Trials of Type 1 Diabetes Vaccines Bring Mixed Results 2Health News:Trials of Type 1 Diabetes Vaccines Bring Mixed Results 3Health News:Mid-Atlantic states' unique plan to replace region's dirtiest trucks 2Health News:Mid-Atlantic states' unique plan to replace region's dirtiest trucks 3Health News:Longest Trial Ever Confirms Mammograms' Benefits 2Health News:Longest Trial Ever Confirms Mammograms' Benefits 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: